Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence

NCT05310591 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT05310591
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05310591 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 15, 2023
Completion date
March 31, 2027
Enrollment
26 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, in relapse, b acute lymphoblastic leukemia